{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:56:00Z","timestamp":1794272160423,"version":"4.9.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003033","name":"Ministerio de Ciencia, Tecnolog\u00eda e Innovaci\u00f3n Productiva","doi-asserted-by":"publisher","award":["SLO\/14\/03"],"award-info":[{"award-number":["SLO\/14\/03"]}],"id":[{"id":"10.13039\/501100003033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010253","name":"Secretar\u00eda de Ciencia y T\u00e9cnica, Universidad de Buenos Aires","doi-asserted-by":"publisher","award":["20020150100012BA"],"award-info":[{"award-number":["20020150100012BA"]}],"id":[{"id":"10.13039\/501100010253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["BI-AR\/15-17-003"],"award-info":[{"award-number":["BI-AR\/15-17-003"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["P1-0208"],"award-info":[{"award-number":["P1-0208"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["L1-8157"],"award-info":[{"award-number":["L1-8157"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["Z1-1859"],"award-info":[{"award-number":["Z1-1859"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","award":["11220150100410"],"award-info":[{"award-number":["11220150100410"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","award":["22920160100046CO"],"award-info":[{"award-number":["22920160100046CO"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005363","name":"Universidad de Buenos Aires","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.neuropharm.2021.108837","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T06:39:53Z","timestamp":1634107193000},"page":"108837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Multitarget 2\u2032-hydroxychalcones as potential drugs for the treatment of neurodegenerative disorders and their comorbidities"],"prefix":"10.1016","volume":"201","author":[{"given":"Fabiola","family":"Kamecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9917-1384","authenticated-orcid":false,"given":"Damijan","family":"Knez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Rademacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefina","family":"Higgs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"\u017dakelj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"de Tezanos Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Andr\u00e9s","family":"Abin-Carriquiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9678-3083","authenticated-orcid":false,"given":"Stanislav","family":"Gobec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Colettis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0190-598X","authenticated-orcid":false,"given":"Mariel","family":"Marder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2021.108837_bib1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson Disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.neuropharm.2021.108837_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0039-1678581","article-title":"Current and future treatments in Alzheimer's disease","volume":"39","author":"Atri","year":"2019","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108837_bib3","series-title":"Permeability-PAMPA. Absorption and Drug Development: Solubility, Permeability, and Charge State","first-page":"319","author":"Avdeef","year":"2012"},{"key":"10.1016\/j.neuropharm.2021.108837_bib4","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/j.drudis.2016.08.001","article-title":"Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders","volume":"21","author":"Bawa","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neuropharm.2021.108837_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0301-0082(94)90081-7","article-title":"The functional role of monoamine oxidases-A and B in the mammalian central nervous system","volume":"42","author":"Berry","year":"1994","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2021.108837_bib6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1021\/acsmedchemlett.9b00039","article-title":"Harnessing polypharmacology with medicinal chemistry","volume":"10","author":"Bolognesi","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2021.108837_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/B978-0-12-386467-3.00002-9","article-title":"Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence","volume":"100","author":"Bortolato","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2021.108837_bib8","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.neurobiolaging.2003.12.027","article-title":"Alzheimer's amyloid \u03b2-peptide (1-42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide","volume":"25","author":"Butterfield","year":"2004","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2021.108837_bib10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3390\/ijms18030551","article-title":"Parkinson's disease: from pathogenesis to pharmacogenomics","volume":"18","author":"Cacabelos","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2021.108837_bib11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/13543776.2018.1427735","article-title":"MAO inhibitors and their wider applications: a patent review","volume":"28","author":"Carradori","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.neuropharm.2021.108837_bib12","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1021\/jm501690r","article-title":"New frontiers in selective human MAO-B inhibitors","volume":"58","author":"Carradori","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12264-013-1423-y","article-title":"Oxidative stress in Alzheimer's disease","volume":"30","author":"Chen","year":"2014","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.neuropharm.2021.108837_bib14","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1021\/jm801590u","article-title":"Chalcones: a valid scaffold for monoamine oxidases inhibitors","volume":"52","author":"Chimenti","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib15","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.bbrc.2011.09.026","article-title":"Isoliquiritigenin, a chalcone compound, is a positive allosteric modulator of GABA A receptors and shows hypnotic effects","volume":"413","author":"Cho","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2021.108837_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejmech.2019.01.039","article-title":"On the role of synthesized hydroxylated chalcones as dual functional amyloid-\u03b2 aggregation and ferroptosis inhibitors for potential treatment of Alzheimer's disease","volume":"166","author":"Cong","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib17","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2021.108837_bib18","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/cmdc.201600182","article-title":"A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules","volume":"11","author":"Daina","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.neuropharm.2021.108837_bib19","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.2174\/0929867325666180111101843","article-title":"Multi-target directed drugs as a modern approach for drug design towards Alzheimer's disease: an update","volume":"25","author":"De Freitas Silva","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0223-5234(03)00012-6","article-title":"High throughput artificial membrane permeability assay for blood-brain barrier","volume":"38","author":"Di","year":"2003","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10822-016-0006-1","article-title":"DockingApp: a user friendly interface for facilitated docking simulations with AutoDock Vina","volume":"31","author":"Di Muzio","year":"2017","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.neuropharm.2021.108837_bib22","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.parkreldis.2017.07.033","article-title":"Neuropathology of Parkinson disease","volume":"46","author":"Dickson","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2021.108837_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108837_bib24","doi-asserted-by":"crossref","first-page":"W337","DOI":"10.1093\/nar\/gkx333","article-title":"ProteinsPlus: a web portal for structure analysis of macromolecules","volume":"45","author":"F\u00e4hrrolfes","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuropharm.2021.108837_bib25","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejphar.2006.04.004","article-title":"Central nervous system depressant action of flavonoid glycosides","volume":"539","author":"Fern\u00e1ndez","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108837_bib26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00702-018-1952-7","article-title":"Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease","volume":"126","author":"Finberg","year":"2019","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2021.108837_bib27","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1039\/C5OB01478F","article-title":"Effects of structural modifications on the metal binding, anti-amyloid activity, and cholinesterase inhibitory activity of chalcones","volume":"13","author":"Fosso","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.phrs.2003.11.017","article-title":"Cholinesterase inhibitors: new roles and therapeutic alternatives","volume":"50","author":"Giacobini","year":"2004","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2021.108837_bib29","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/gps.935","article-title":"Cholinergic function and Alzheimer's disease","volume":"18","author":"Giacobini","year":"2003","journal-title":"Int. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.neuropharm.2021.108837_bib30","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1080\/13607863.2018.1506741","article-title":"Stress and verbal memory in patients with Alzheimer's disease: different role of cortisol and anxiety","volume":"23","author":"G\u00f3mez-Gallego","year":"2019","journal-title":"Aging Ment. Health"},{"key":"10.1016\/j.neuropharm.2021.108837_bib31","doi-asserted-by":"crossref","first-page":"112650","DOI":"10.1016\/j.ejmech.2020.112650","article-title":"Chalcones: unearthing their therapeutic possibility as monoamine oxidase B inhibitors","volume":"205","author":"Guglielmi","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejmech.2016.02.038","article-title":"Design and synthesis of novel chalcones as potent selective monoamine oxidase-B inhibitors","volume":"114","author":"Hammuda","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib33","doi-asserted-by":"crossref","first-page":"8689","DOI":"10.1039\/C4OB01377H","article-title":"Profiling substrate specificity of two series of phenethylamine analogs at monoamine oxidase-A and B","volume":"12","author":"Heuson","year":"2014","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2019.e01376","article-title":"Chalcone derivatives: synthesis, in vitro and in vivo evaluation of their anti-anxiety, anti-depression and analgesic effects","volume":"5","author":"Higgs","year":"2019","journal-title":"Heliyon"},{"key":"10.1016\/j.neuropharm.2021.108837_bib35","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1021\/acsmedchemlett.1c00238","article-title":"Promising non-cytotoxic monosubstituted chalcones to target monoamine oxidase-B","volume":"12","author":"Iacovino","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2021.108837_bib36","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1472-8206.2008.00639.x","article-title":"Evaluation of chalcones - a flavonoid subclass, for, their anxiolytic effects in rats using elevated plus maze and open field behaviour tests","volume":"22","author":"Jamal","year":"2008","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108837_bib37","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.3390\/nu9101122","article-title":"Resveratrol and amyloid-beta: mechanistic insights","volume":"9","author":"Jia","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.neuropharm.2021.108837_bib38","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neurobiolaging.2019.10.008","article-title":"Apathy and anxiety are early markers of Alzheimer's disease","volume":"85","author":"Johansson","year":"2020","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2021.108837_bib39","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1021\/jm2016073","article-title":"A synthetic chalcone as a potent inducer of glutathione biosynthesis","volume":"55","author":"Kachadourian","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jphotochem.2021.113137","article-title":"2\u2019-Hydroxy-4\u2019,5\u2019-dimethyl-4-dimethylaminochalcone, a novel fluorescent flavonoid with capacity to detect aluminium in cells and modulate Alzheimer's disease targets","volume":"409","author":"Kamecki","year":"2021","journal-title":"J. Photochem. Photobiol. A Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib41","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1016\/j.bmc.2015.06.010","article-title":"Structure-based development of nitroxoline derivatives as potential multifunctional anti-Alzheimer agents","volume":"23","author":"Knez","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib42","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1021\/acs.jmedchem.9b01886","article-title":"Stereoselective Aativity of 1-propargyl-4-styrylpiperidine-like analogues that can discriminate between monoamineo Oxidase isoforms A and B","volume":"63","author":"Knez","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13321-016-0139-1","article-title":"AutoDock VinaXB: implementation of XBSF, new empirical halogen bond scoring function, into AutoDock Vina","volume":"8","author":"Koebel","year":"2016","journal-title":"J. Cheminf."},{"key":"10.1016\/j.neuropharm.2021.108837_bib44","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1080\/14756366.2020.1797711","article-title":"Design, synthesis, and evaluation of 1, 4-benzodioxan-substituted chalcones as selective and reversible inhibitors of human monoamine oxidase-B","volume":"35","author":"Kong","year":"2020","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib45","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.bmc.2016.11.032","article-title":"N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: potential multifunctional anti-Alzheimer\u2019s agents","volume":"25","author":"Ko\u0161ak","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1385\/MN:30:1:077","article-title":"Perspectives on MAO-B in aging and neurological disease: where do we go from here?","volume":"30","author":"Kumar","year":"2004","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2021.108837_bib47","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0022-1759(84)90477-0","article-title":"Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens","volume":"67","author":"Landegren","year":"1984","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.neuropharm.2021.108837_bib48","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/cns.13058","article-title":"Novel synthetic chalcone-coumarin hybrid for A\u03b2 aggregation reduction, antioxidation, and neuroprotection","volume":"24","author":"Lee","year":"2018","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuropharm.2021.108837_bib49","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/pro.5560020312","article-title":"Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution","volume":"2","author":"Levine","year":"1993","journal-title":"Protein Sci."},{"key":"10.1016\/j.neuropharm.2021.108837_bib50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.neuropharm.2021.108837_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112787","article-title":"A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer\u2019s disease agents: a review","volume":"206","author":"Manzoor","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib52","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1871524915666151002124443","article-title":"Monoamine oxidase inhibitory action of chalcones: a mini review","volume":"16","author":"Mathew","year":"2015","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib53","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.ijbiomac.2017.05.162","article-title":"Monoamine oxidase inhibitory activity of methoxy-substituted chalcones","volume":"104","author":"Mathew","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.neuropharm.2021.108837_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201900177","article-title":"Emerging therapeutic potentials of dual-acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases","volume":"352","author":"Mathew","year":"2019","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.neuropharm.2021.108837_bib55","doi-asserted-by":"crossref","first-page":"432","DOI":"10.2174\/1871527318666190610111246","article-title":"Perspective design of chalcones for the management of CNS disorders: a mini-review","volume":"18","author":"Mathew","year":"2019","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"key":"10.1016\/j.neuropharm.2021.108837_bib56","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/0006-2952(90)90716-X","article-title":"Chrysin (5,7-di-OH-flavone), a naturally-occurring ligand for benzodiazepine receptors, with anticonvulsant properties","volume":"40","author":"Medina","year":"1990","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108837_bib57","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1002\/jps.21745","article-title":"In vivo, in vitro and in silico methods for small molecule transfer across the BBB","volume":"98","author":"Mensch","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.neuropharm.2021.108837_bib59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00702-014-1362-4","article-title":"Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression","volume":"123","author":"Naoi","year":"2016","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2021.108837_bib60","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.3390\/molecules25102356","article-title":"Novel class of chalcone oxime ethers as potent monoamine oxidase-B and acetylcholinesterase inhibitors","volume":"25","author":"Oh","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.neuropharm.2021.108837_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103335","article-title":"Design, synthesis and biological evaluation of oxygenated chalcones as potent and selective MAO-B inhibitors","volume":"93","author":"Parambi","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav0316","article-title":"Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease","volume":"5","author":"Park","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.neuropharm.2021.108837_bib63","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera - a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib64","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejphar.2006.06.025","article-title":"Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets","volume":"545","author":"Ramassamy","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108837_bib65","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.pnpbp.2016.02.005","article-title":"Molecular aspects of monoamine oxidase-B","volume":"69","author":"Ramsay","year":"2016","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2021.108837_bib66","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/0024-3205(81)90744-X","article-title":"High affinity renal [3H]flunitrazepam binding: characterization, localization, and alteration in hypertension","volume":"28","author":"Regan","year":"1981","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2021.108837_bib67","first-page":"337","article-title":"Parkinson's disease","volume":"103","author":"Reich","year":"2019","journal-title":"Med. Clin."},{"key":"10.1016\/j.neuropharm.2021.108837_bib68","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1021\/acs.jmedchem.8b00357","article-title":"Tight-binding inhibition of human monoamine oxidase B by chromone analogs: a kinetic, crystallographic, and biological analysis","volume":"61","author":"Reis","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib69","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1600-0404.1989.tb01781.x","article-title":"Neurochemical perspectives to the function of monoamine oxidase","volume":"80","author":"Riederer","year":"1989","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.neuropharm.2021.108837_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5607\/en.2011.20.1.1","article-title":"MAO-inhibitors in Parkinson's disease","volume":"20","author":"Riederer","year":"2011","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.neuropharm.2021.108837_bib71","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/j.1471-4159.1986.tb01747.x","article-title":"Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with L-deprenyl","volume":"46","author":"Riederer","year":"1986","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib72","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1016\/j.bmcl.2009.09.074","article-title":"New stilbene dimers against amyloid fibril formation","volume":"20","author":"Rivi\u00e8re","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.neuropharm.2021.108837_bib73","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.bmc.2006.09.069","article-title":"Inhibitory activity of stilbenes on Alzheimer's \u03b2-amyloid fibrils in vitro","volume":"15","author":"Rivi\u00e8re","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib74","doi-asserted-by":"crossref","first-page":"W443","DOI":"10.1093\/nar\/gkv315","article-title":"PLIP: fully automated protein\u2013ligand interaction profiler","volume":"43","author":"Salentin","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuropharm.2021.108837_bib75","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.ejmech.2019.06.026","article-title":"Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease","volume":"178","author":"Sang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101256","article-title":"Monoamine oxidases in age-associated diseases: new perspectives for old enzymes","volume":"66","author":"Santin","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuropharm.2021.108837_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101256","article-title":"Monoamine oxidases in age-associated diseases: new perspectives for old enzymes","volume":"66","author":"Santin","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuropharm.2021.108837_bib78","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ardp.201600088","article-title":"Identification of indole-based chalcones: discovery of a potent, selective, and reversible class of MAO-B inhibitors","volume":"349","author":"Sasidharan","year":"2016","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.neuropharm.2021.108837_bib79","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ijbiomac.2017.11.159","article-title":"Discovery of potent and reversible MAO-B inhibitors as furanochalcones","volume":"108","author":"Suresh","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.neuropharm.2021.108837_bib80","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00702-018-1853-9","article-title":"Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease","volume":"125","author":"Sz\u00f6k\u0151","year":"2018","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2021.108837_bib81","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-2006-962604","article-title":"Isolation of monoamine oxidase inhibitors from Glycyrrhiza uralensis roots and the structure-activity relationship","volume":"53","author":"Tanaka","year":"1987","journal-title":"Planta Med."},{"key":"10.1016\/j.neuropharm.2021.108837_bib82","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejmech.2018.01.003","article-title":"Privileged scaffolds as MAO inhibitors: retrospect and prospects","volume":"145","author":"Tripathi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108837_bib83","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bcp.2017.04.004","article-title":"Natural product-based amyloid inhibitors","volume":"139","author":"Velander","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108837_bib58","series-title":"US4900822A - New Hydrolase Substrates","author":"von der Heltz","year":"1990"},{"key":"10.1016\/j.neuropharm.2021.108837_bib84","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1021\/ci990307l","article-title":"Prediction of physicochemical parameters by atomic contributions","volume":"39","author":"Wildman","year":"1999","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"10.1016\/j.neuropharm.2021.108837_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2020.128954","article-title":"Structural characterization, electronic properties, and anxiolytic-like effect in adult zebrafish (Danio rerio) of cinnamaldehyde chalcone","volume":"1222","author":"Xavier","year":"2020","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.neuropharm.2021.108837_bib86","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s00702-018-1942-9","article-title":"Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases","volume":"125","author":"Youdim","year":"2018","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2021.108837_bib87","doi-asserted-by":"crossref","first-page":"S287","DOI":"10.1038\/sj.bjp.0706464","article-title":"Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness","volume":"147","author":"Youdim","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108837_bib88","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","article-title":"The therapeutic potential of monoamine oxidase inhibitors","volume":"7","author":"Youdim","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108837_bib89","doi-asserted-by":"crossref","first-page":"7762","DOI":"10.1021\/acs.chemrev.7b00020","article-title":"Chalcone: a privileged structure in medicinal chemistry","volume":"117","author":"Zhuang","year":"2017","journal-title":"Chem. Rev."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821003920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821003920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:36:00Z","timestamp":1778657760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390821003920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":89,"alternative-id":["S0028390821003920"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108837","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multitarget 2\u2032-hydroxychalcones as potential drugs for the treatment of neurodegenerative disorders and their comorbidities","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108837","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108837"}}